SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,620.00
-70.00 (-1.90%)
At close: Feb 27, 2026
44.22%
Market Cap 500.03B
Revenue (ttm) 7.84B
Net Income (ttm) -23.24B
Shares Out 138.13M
EPS (ttm) -168.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,038,512
Average Volume 4,214,326
Open 3,690.00
Previous Close 3,690.00
Day's Range 3,600.00 - 3,725.00
52-Week Range 1,873.00 - 5,400.00
Beta 0.27
RSI 47.34
Earnings Date Mar 20, 2026

About SillaJen

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2024, SillaJen's revenue was 3.93 billion, a decrease of -0.33% compared to the previous year's 3.94 billion. Losses were -26.53 billion, 30.2% more than in 2023.

Financial Statements

News

There is no news available yet.